National Vision(EYE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In fiscal 2025, net revenue grew 9% to $1.99 billion, with adjusted operating income increasing 56% to $102.5 million, resulting in an adjusted EPS of $0.80 compared to $0.52 in 2024 [6][40] - For Q4, net revenue increased 15.1% to $503 million, with adjusted operating income rising to $17.6 million and adjusted EPS at $0.15 per share, up from a loss of $0.04 per share last year [7][39] Business Line Data and Key Metrics Changes - The number of exams performed by the doctor network increased, contributing to healthy profit expansion, with average ticket growth of 6% for the year [5][9] - Managed care comp sales grew low double digits in 2025, with 42% of revenues attributable to managed care [9][10] Market Data and Key Metrics Changes - Traffic declined 0.5% overall for the year, reflecting declines with self-pay customers, while traffic growth was observed in managed care, progressive, and outside RX customers [9][10] - The company ended the year with approximately 40% of frames priced above $99, up from 20% at the start of the year [11] Company Strategy and Development Direction - The company is focused on four growth vectors: expanding with underdeveloped customers, evolving product offerings, enhancing customer experience, and new store growth [8][10] - A significant pivot was made to attract more profitable customer cohorts, with a transformation in merchandising strategy to better meet their needs [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to continue expanding market share and improving profitability despite challenges in the cash pay customer segment [5][52] - The company anticipates continued momentum from transformation initiatives, with a fiscal 2026 revenue outlook between $2.03 billion and $2.09 billion [42] Other Important Information - The company repaid $101.3 million in long-term debt during fiscal 2025, ending the year with a net debt to adjusted EBITDA of 1.1 times [40][41] - A new share repurchase authorization was approved for up to $50 million until December 28, 2030 [41] Q&A Session Summary Question: Concerns about the trade-off between growth from insurance customers versus traditional customers - Management noted a strong start in Q4 but observed some slowing in December, particularly with cash pay customers, while managed care consumers remained strong [50][52] Question: Expectations for cash pay customer performance and impact of tax refunds - Management expects cash pay customers to comp positively, with optimism about tax refunds benefiting overall consumption [54][56] Question: Breakdown of net traffic between profitable target customers and traditional customers - Management indicated a multi-year strategy to shift customer cohorts, focusing on acquiring more profitable customers [63] Question: Insights on SG&A leverage and cost-cutting measures - Management highlighted a healthy mix of sales growth and cost-cutting measures, with expectations for ongoing precise spending [66] Question: Projections for a softer end market and its impact on business - Management expressed confidence in controlling their destiny, noting growth in eye exams despite industry declines, and emphasized the introduction of premium products [72][74]